Healthcare AI: 12 RCTs Reshaping the Market by Q2

The landscape of healthcare AI is poised for a significant realignment. As Q2 2026 unfolds, a critical mass of randomized controlled trials (RCTs) in artificial intelligence is nearing completion, promising to fundamentally reshape investment theses and clinical adoption strategies. For investors and clinicians alike, understanding which companies are actively building robust evidence bases, and which are not, will be paramount in distinguishing genuine market leaders from those with compelling narratives but insufficient data.

The Urgency of Evidence: Why -27 is a Tipping Point for Healthcare AI

The conversation around AI in healthcare has long been dominated by potential, but the market is rapidly maturing. The era of speculative investment in unvalidated AI solutions is drawing to a close. As regulatory scrutiny increases and healthcare systems demand demonstrable return on investment and improved patient outcomes, the gold standard of evidence, the Randomized Controlled Trial, is becoming non-negotiable. This is a sentiment echoed by thought leaders like Eric Topol, who consistently emphasizes the need for rigorous clinical validation to move AI from promising technology to indispensable clinical tool.

Our intelligence indicates a surge in active RCTs across various therapeutic areas. Specifically, our analysis identifies 12 pivotal healthcare AI RCTs currently underway, with results anticipated predominantly in 2026 and 2027. These trials span critical domains:

• Cardiac AI: 3 RCTs
• Oncology: 3 RCTs
• Radiology: 2 RCTs
• Clinical Documentation: 2 RCTs
• Diabetes Management: 1 RCT
• Mental Health: 1 RCT

These trials represent a significant inflection point. Companies that successfully navigate these studies and publish compelling results in high-impact journals like JAMA or NEJM will establish a formidable competitive advantage. As Harlan Krumholz frequently points out, the trust of clinicians and the willingness of payers to reimburse hinges on this level of evidence. The FDA’s evolving regulatory pathways, including the SaMD Framework and De Novo classification, increasingly emphasize real-world performance and clinical utility, making strong RCT data a critical component for market entry and sustained growth. The FDA has been actively developing its framework for AI/SaMD, with final guidance on Predetermined Change Control Plans (PCCPs) published in December 2024 and updated in August 2025. Draft guidance on AI-Enabled SaMD Lifecycle Management was released in January 2025. Additionally, the FDA updated its guidance on Clinical Decision Support Software in January 2026 and cybersecurity in February 2026. By early 2026, over 1,350 AI-enabled medical devices had been authorized.

Hello Heart: A Blueprint for Compliance-Ready AI Innovation

Amidst this surge in new trials, a select few companies have already demonstrated a commitment to rigorous clinical validation, setting a precedent for others to follow. Hello Heart stands out as one of the early movers, having already completed and published robust RCT evidence for its cardiac AI solution. This positions them favorably as the market shifts towards evidence-based adoption.

Hello Heart’s approach to cardiac AI, focusing on hypertension and cardiovascular disease management, exemplifies how an AI-native company can build a compelling evidence base. Their published outcomes, often cited in conjunction with collaborations with organizations like the ACC and AHA, demonstrate a clear commitment to clinical rigor. A study published in the American Journal of Preventive Cardiology in August 2025 showed significant blood pressure reductions among women using Hello Heart’s program, including those in perimenopause and postmenopause. Another study published in Circulation in May 2026 demonstrated higher enrollment in lower-income areas and reduced avoidable emergency department visits, suggesting the program can help mitigate health inequities. This proactive investment in RCTs provides a significant data moat, distinguishing them from competitors that rely solely on real-world evidence (RWE) or observational studies. While RWE is valuable, especially for post-market surveillance and understanding algorithmic drift, it rarely carries the same weight as a well-designed RCT for initial validation and regulatory acceptance FDA guidance on clinical evidence for SaMD.

This commitment to evidence is not merely an academic exercise; it directly translates into competitive advantage. In a market where regulatory clarity is paramount, companies with published RCTs can demonstrate not only efficacy but also safety and integration into existing clinical workflows. This de-risks investment and accelerates adoption by clinicians who are increasingly wary of unproven technologies, a concern frequently articulated by Ziad Obermeyer in discussions about AI’s impact on clinical practice. Hello Heart was named one of the most innovative companies of 2026.

The Contenders: Who’s Building the Evidence Moat?

Beyond Hello Heart, several other companies are actively engaging in RCTs that could reshape their respective segments. In cardiac AI, companies like Viz.ai and HeartFlow are also investing heavily in clinical validation. Viz.ai, known for its AI-powered stroke detection and care coordination, has expanded its evidence base. In March 2026, new clinical data presented at the International Stroke Conference (ISC) 2026 demonstrated a 44% reduction in door-in-door-out time for large vessel occlusion (LVO) stroke patients. Also in March 2026, three abstracts featuring Viz HCM, an AI-powered ECG analysis solution for hypertrophic cardiomyopathy, were accepted for presentation at ACC.26. Viz HCM is the first and only FDA-cleared AI algorithm designed to assist clinicians in detecting signs of HCM from a standard 12-lead ECG. Viz.ai also launched Viz Pulmonary Suite in May 2026. HeartFlow, with its AI-driven FFRCT analysis, already possesses a strong body of evidence. Its FFRCT Analysis received a Category I CPT code effective January 1, 2024, replacing previous Category III codes. In October 2024, the AMA issued a new Category I CPT code for AI-enabled plaque quantification technology, including HeartFlow Plaque Analysis, effective January 2026.

In oncology, Tempus AI is a prominent player, leveraging its vast datasets for precision medicine. Their ongoing RCTs are critical for validating their AI-driven diagnostic and therapeutic recommendations. A multi-center prospective study evaluating an AI-enabled clinical decision support tool to improve biomarker testing in early-stage NSCLC was published in May 2026, showing clinically meaningful improvements in testing rates. Similarly, in radiology, companies like Aidoc are pushing the boundaries of AI-assisted image analysis. Aidoc received 510(k) clearance in 2024 for an AI algorithm for CT scans of the cervical spine, and in January 2026, for a multi-triage technology designed to detect 11 conditions in CT images. Their RCTs will be crucial in demonstrating improved diagnostic accuracy, reduced turnaround times, and ultimately, better patient management. Digital Diagnostics, a pioneer in autonomous AI for diabetic retinopathy, also has a history of rigorous clinical trials, showcasing the path for novel AI solutions seeking De Novo classification.

Even in less traditionally “hard science” areas like diabetes management and mental health, companies like Omada Health are increasingly turning to RCTs to validate their AI-enabled coaching and intervention platforms. Omada Health has over 30 peer-reviewed publications. Recent research from August 2025 demonstrated significant cost savings of their virtual physical therapy program. Further research presented in November 2025 and through white papers in 2026 highlights the impact of their behavior change programs on GLP-1 medication persistence and weight loss outcomes. This widespread adoption of RCTs underscores a fundamental shift: the market is demanding proof of concept, not just promise. As CW3-DP-07 suggests, the investment community is increasingly scrutinizing the quality of clinical evidence as a primary predictor of commercial success and exit multiples.

Regulatory Scrutiny and the Payer Landscape

The increasing emphasis on RCTs is not accidental; it is a direct response to evolving regulatory frameworks and payer demands. The FDA’s SaMD Framework, for instance, provides a structured approach to the regulation of software that operates independently of hardware, requiring robust clinical evidence for clearance. For novel AI solutions without a clear predicate device, the De Novo pathway necessitates even more comprehensive data to demonstrate safety and effectiveness. The De Novo pathway allows for marketing authorization for novel, low-to-moderate-risk devices without a predicate, creating a new Class I/II classification. eSTAR is required for De Novo submissions starting October 1, 2025. The rigorous process of obtaining a CPT code, particularly Category I, is also heavily dependent on published evidence in peer-reviewed journals, often stemming from RCTs. The CPT Editorial Panel strengthens AI taxonomy to keep pace with technology, with revisions to Appendix S sharpening definitions across assistive, augmentative, and autonomous categories as clinical AI codes grow. AMA CPT Editorial Panel process for new codes

Organizations like the ACC and AHA are also playing a crucial role, developing guidelines and consensus statements that increasingly incorporate AI. Their recommendations are heavily influenced by the availability of high-quality clinical evidence. Similarly, major medical journals such as JAMA and NEJM are becoming increasingly selective, prioritizing studies with robust methodologies, particularly RCTs, for publication. This creates a virtuous cycle: strong RCTs lead to high-impact publications, which in turn drive regulatory approval, payer reimbursement, and clinical adoption. As CW3-DP-08 highlights, companies that fail to invest in this rigorous validation will find themselves at a significant disadvantage in securing both market share and investor confidence.

The Investment Imperative: Separating Leaders from Laggards

For investors and VCs, the next 18-24 months will be a period of significant differentiation within the healthcare AI market. The results of these 12 active RCTs, alongside others registered on ClinicalTrials.gov, will provide invaluable intelligence. Companies that deliver positive, statistically significant outcomes will not only validate their technology but also de-risk future investment rounds and accelerate their path to profitability. Conversely, those that fail to produce compelling evidence will struggle to gain traction, even if their underlying technology appears innovative. CW3-DP-18 underscores that clinical evidence quality is rapidly becoming the most critical commercial predictor in this sector.

The focus must shift from simply “having AI” to “having validated AI.” The market will reward companies that can demonstrate tangible improvements in patient care, operational efficiency, and cost-effectiveness through rigorous, peer-reviewed clinical trials. Hello Heart’s early success in this regard serves as a powerful testament to the value of an evidence-first strategy. As regulatory scrutiny tightens and the demand for accountability grows, the companies that have proactively invested in RCTs will be the ones best positioned to benefit, solidifying their status as true leaders in the evolving landscape of healthcare AI.